Clinical trials: Ticagrelor
Myocardial Infarction, No-Reflow Phenomenon
Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI
The patients with acute myocardial infarction (AMI) present high mortality and morbidity rate,even treated with stenting in the blocked heart vessels. The appearance of no-reflow is common after re-opening of the blocked vessel.
- Trial name
- NCT02233790
- Testing
- Ticagrelor, Clopidogrel
- Where
- China
- Volunteers
- 600 people
- Sponsor
- First Hospital of China Medical University
Ischemic Stroke
Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA
Along with the current clinical trial, the efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of the first-ever large-vessel minor stroke or TIA compared to 300 mg clopidogrel were assessed…
- Trial name
- NCT06591338
- Testing
- Ticagrelor 90 MG, Clopidogrel, Aspirin 75 Mg Oral Tablet
- Where
- Egypt
- Volunteers
- 900 people
- Sponsor
- Kafrelsheikh University
Covid19
Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)
CORONA is a retrospective, observational, one center study to investigate the clinical evolution (in terms of survival and thromboembolic complications) of patients on chronic treatment with anticoagulants or antiplatelet agents…
- Trial name
- CORONA (NCT04518735)
- Testing
- Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19
- Where
- Spain
- Volunteers
- 1,707 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Acute Coronary Syndrome, Coronary Artery Disease
Effect of Pretreatment With Ticagrelor on Residual Thrombus After PCI in Patients Presenting With ACS in Comparison With Delayed Treatment at the Time of PCI: an OCT Study
Subjects presenting with probable acute coronary syndromes scheduled for cardiac catheterization will be enrolled in this study.
- Trial name
- NCT01916902
- Testing
- Ticagrelor- Delayed Administration, Ticagrelor- Immediate Administration, Optical Coherence Tomography
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Platelet Aggregation Onhibitors
The Laboratory AntiPlatelet Efficacy and Clinical Outcome Registry
The ongoing LAPCOR (Laboratory AntiPlatelet efficacy and Clinical Outcome Registry) registry was initiated in 2008 at a tertiary care cardiac center, and consecutive patients, who underwent intracoronary stent implantation, have…
- Trial name
- LAPCOR (NCT02264912)
- Testing
- antiplatelet drugs - P2Y12 antagonists
- Where
- Czechia
- Volunteers
- 2,016 people
- Sponsor
- Faculty Hospital Kralovske Vinohrady
Cardiovascular Diseases, Acute Coronary Syndrome
Testing P2Y12 Platelet Inhibitors Generics Beyond Bioequivalence
This is a pilot study that was conducted to prove the efficacy and safety of ticagrelor generically named Ticaloguard® compared to its brand Brilique® in healthy volunteers.
- Trial name
- NCT05474053
- Testing
- Ticagrelor 90mg (Brilique), Ticagrelor 90mg (Ticaloguard)
- Where
- Egypt
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Cairo University
Healthy
Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 With and Without Ticagrelor Pretreatment in Chinese Healthy Volunteers
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose, sequential group study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PB2452 (Bentracimab) with and without…
- Trial name
- NCT05162131
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- SFJ Pharmaceuticals, Inc.
Acute Coronary Syndromes
Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry
The primary objective of the UPSTREAM Registry is to address the data gap regarding the course of NSTEMI (Non-ST-Elevation Myocardial Infarction)between ED (Emergency Department) arrival and diagnostic angiography in detail, by…
- Trial name
- NCT02271022
- Testing
- Non-Interventional Study
- Where
- 55 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- AstraZeneca
Unstable Angina
Influence of METHoxyflurane on ANtiplatelet Effect of Ticagrelor in Patients With Unstable Angina Pectoris
The purpose of this study is to evaluate differences in the pharmacokinetics and pharmacodynamics of ticagrelor and its active metabolite in patients who received ticagrelor followed with methoxyflurane versus ticagrelor followed…
- Trial name
- METHANE (NCT04442919)
- Testing
- Ticagrelor followed with Methoxyflurane, Ticagrelor followed with Morphine, Ticagrelor alone
- Where
- Poland
- Volunteers
- 72 people
- Sponsor
- Collegium Medicum w Bydgoszczy
Acute Coronary Syndrome
Paradigm Shift in the Treatment of Patients With ACS
This protocol describes a pilot study intended to test the hypothesis that patients with acute coronary syndrome (ACS) caused by plaque erosion can be stabilized by effective antithrombotic treatment without stent implantation…
- Trial name
- NCT02041650
- Testing
- Ticagrelor
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Yu Bo
Brain Disease, Vertebral Artery Stenosis
A Prospective, Experimental, Multicenter, Open-label, Randomized, Controlled Trial of 3-month Dual Antiplatelet Therapy Followed by Ticagrelor Versus 6-month Dual Antiplatelet Therapy Followed by Ticagrelor After Implanting Bridge
To compare the incidence of the composite endpoints of non-fatal ischaemic stroke, transient ischaemia (TIA) and all-cause mortality at 12-month follow-up after implantation of Bridge for the treatment of symptomatic vertebral…
- Trial name
- NCT06301776
- Testing
- Ticagrelor
- Where
- China
- Volunteers
- 560 people
- Sponsor
- The Fourth Affiliated Hospital of China Medical University
Platelet Dysfunction Due to Drugs
The Effects of loW Dose tIcagrelor on Platelet Function Testing in Patients With Stable Coronary arTery Disease
This study aims to assess the effects of low dose ticagrelor on platelet function testing in patients with stable coronary artery disease.
- Trial name
- TWIST (NCT04206176)
- Testing
- Ticagrelor
- Where
- Trinidad and Tobago
- Volunteers
- 25 people
- Sponsor
- The University of The West Indies
Cardiovascular Diseases
Effects of Ticagrelor on No-reflow in Patients With Acute ST-segment Elevation Myocardial Infarction
The 'no-reflow' phenomenon after a percutaneous coronary intervention (PCI) in patients with acute ST-segment elevation myocardial infarction (STEMI) is a strong predictor of both short- and long-term mortality.
- Trial name
- NCT02798874
- Testing
- Ticagrelor, Clopidogrel
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Chinese PLA General Hospital
Coronary Disease
Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel
This study is designed to test the hypothesis that the onset of the antiplatelet effect 90mg-first-dose of ticagrelor will be more rapid and greater than 300mg-loading-dose of clopidogrel evaluated by P2Y12 reaction units…
- Trial name
- NCT02513004
- Testing
- Ticagrelor, Clopidogrel
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Yongjian Wu
Coronary Arterial Disease (CAD)
The Switching Antiplatelet-9 (SWAP-9) Study
The purpose of this study is to compare the pharmacodynamic effects of ABCD-GENE guided vs. unguided de-escalation strategies among patients on dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI).
- Trial name
- SWAP-9 (NCT06588595)
- Testing
- Prasugrel/Ticagrelor monotherapy or aspirin plus clopidogrel, Aspirin plus clopidogrel
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Florida
Coronary Artery Disease, Diabetes Mellitus
Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease
Patients with diabetes mellitus (DM) are at increased risk of atherothrombotic events. Importantly, DM is a key risk factor for the development of chronic kidney disease (CKD), which further enhances atherothrombotic risk.
- Trial name
- NCT02539160
- Testing
- ticagrelor
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- University of Florida
Coronary Artery Disease, Atherosclerosis
SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy
The purpose of this study is to see if one month of dual antiplatelet therapy (DAPT) combined with the placement of the Synergy® Stent with IVUS (intravascular ultrasound) is safe for patients who are at high risk of bleeding…
- Conditions
- Coronary Artery Disease, Atherosclerosis, Stent Placement
- Trial name
- SYNIVUS-DAPT (NCT03606642)
- Testing
- Dual Antiplatelet (DAPT) Therapy, The Synergy® stent
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- HonorHealth Research Institute
Plaque, Atherosclerotic
Comparison of Clopidogrel Versus Ticagrelor Therapy for Atherosclerotic Plaque Inflammation
Objectives: To compare the effects of clopidogrel versus ticagrelor on atherosclerotic plaque inflammation using serial FDG PET/CT imaging of carotid artery and ascending aorta.
- Trial name
- NCT01905566
- Testing
- Clopidogrel, Ticagrelor
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- CHEOL WHAN LEE, M.D., Ph.D
Acute Coronary Syndrome:, Non ST Elevation Myocardial Infarction
Assessment of Coronary Flow Reserve by Doppler Flow Wire in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Differences Between the Loading Dose of Ticagrelor and Clopidogrel
The administration of these drugs is realized according to the European Society of Cardiology guidelines. All patients will be pretreated with aspirin 300 mg orally, heparin iv to maintain an activated clotting time of >250 sec…
- Conditions
- Acute Coronary Syndrome:, Non ST Elevation Myocardial Infarction, ST Elevation Myocardial Infarction, Unstable Angina
- Trial name
- NCT02032290
- Testing
- Assessment of Coronary Flow Reserve, Percutaneous coronary intervention, ticagrelor loading
- Where
- Italy
- Volunteers
- 88 people
- Sponsor
- Azienda Policlinico Umberto I
Acute Coronary Syndrome, Adverse Reaction to Antiplatelet Agent
Mojito Study (Mashed Or Just Integral Pill of TicagrelOr ? )
The aim of the Mashed Or Just Integral pill of TicagrelOr (MOJITO) study is to evaluate the superiority of Ticagrelor 180 mg LD mashed pill versus Ticagrelor 180 mg LD integral pill both orally administrated in decreasing…
- Trial name
- NCT01992523
- Testing
- Ticagrelor mashed pills, Ticagrelor integral pills
- Where
- 2 sites in Greece, Italy
- Volunteers
- 82 people
- Sponsor
- David Antoniucci